AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy
- 1 February 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 19 (1) , 14-19
- https://doi.org/10.1097/01.qco.0000200295.30285.13
Abstract
Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer. In addition a number of other cancers occur at increased frequency in this population group but are not AIDS-defining illnesses. This review discusses the impact of highly active antiretroviral therapy on the epidemiology and outcome of AIDS-defining cancers. The incidence of both Kaposi's sarcoma and non-Hodgkin's lymphoma has declined in the era of highly active antiretroviral therapy and the outcome of both tumours has improved. Moreover, highly active antiretroviral therapy alone produces a response in a majority of antiretroviral-naïve patients with Kaposi's sarcoma. In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths. As people with HIV live longer with highly active antiretroviral therapy, an increased incidence of other non AIDS-defining cancers that have no known association with oncogenic infections is becoming apparent. For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers – particularly Kaposi's sarcoma and non-Hodgkin's lymphoma – may be balanced by the increasing numbers of non AIDS-defining cancers.Keywords
This publication has 43 references indexed in Scilit:
- A Prognostic Index for Systemic AIDS-Related Non-Hodgkin Lymphoma Treated in the Era of Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2005
- AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre–Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard ChemotherapyJournal of Clinical Oncology, 2005
- Protease inhibitors potentiate chemotherapy-induced neutropeniaBlood, 2004
- Antiretroviral Treatment Regimens and Immune Parameters in the Prevention of Systemic AIDS-Related Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2004
- Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biologyBlood, 2003
- The incidence of lymphoma in the UK haemophilia population between 1978 and 1999AIDS, 2002
- Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphomaAIDS, 2002
- Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected AdultsJNCI Journal of the National Cancer Institute, 2000
- Changes in acquired immunodeficiency syndrome–related lymphoma since the introduction of highly active antiretroviral therapyBlood, 2000
- The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus?related systemic non-Hodgkin lymphomaCancer, 1999